Wall Street analyst estimates for Aptevo Therapeutics Inc. (APVO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-3.71 | ||
| 2026-08-14 | $-5.31 | $-6.01 | +11.6% |
| 2026-05-13 | $-6.41 | $-5.60 | -14.5% |
| 2026-03-20 | $1684.47 | $-8.09 | +20921.6% |
| 2025-11-06 | $-40.11 | $-37.59 | -6.7% |
| 2025-08-11 | $-151.20 | $-83.20 | -81.7% |
| 2025-05-15 | $-1579.14 | $-4.21 | -37409.3% |
| 2025-03-04 | $-3218.40 | $-7.75 | -41427.7% |
Valuation Ratios
| Price / Book | 0.24 |
| EV / EBITDA | 0.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.4M | $14.7M | $23.1M | 0 | $4.3M | $12.3M | $3.1M | 0 | 0 | 0 |
| Cost of Revenue | $24.2M | $5.0M | $11.2M | $2.2M | $17.9M | 0 | 0 | 0 | $352000 | $240000 |
| Gross Profit | $12.3M | $9.6M | $11.9M | -$2.2M | -$13.5M | $12.3M | $3.1M | 0 | -$352000 | -$240000 |
| Research & Development | $29.5M | $29.0M | $35.4M | $24.8M | $17.9M | $19.0M | $17.9M | $17.1M | $14.4M | $14.5M |
| Selling, General & Admin | $38.7M | $34.6M | $28.1M | $14.0M | $14.0M | $14.7M | $13.9M | $11.8M | $10.2M | $11.8M |
| Operating Expenses | $68.2M | $63.6M | $63.5M | $38.7M | $14.0M | $33.7M | $31.8M | $28.9M | $24.2M | $26.1M |
| Operating Income | -$126.9M | -$53.9M | -$51.7M | -$41.0M | -$27.5M | -$21.4M | -$28.6M | -$28.9M | -$24.6M | -$26.3M |
| EBITDA | -$64.4M | -$50.8M | -$49.3M | -$40.8M | -$26.2M | -$28.3M | $7.9M | -$18.1M | -$23.8M | -$25.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$127.8M | -$55.9M | -$53.7M | -$43.1M | -$30.9M | -$29.4M | $7.0M | -$18.6M | -$24.1M | -$26.0M |
| Income Tax | -$15.3M | -$23.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$112.4M | $7.0M | -$53.7M | -$44.7M | -$17.8M | -$28.5M | $8.0M | -$17.4M | -$24.1M | -$26.0M |
| EPS | $-45538416.00 | $-17584638.00 | $-19578811.00 | $-125727793.00 | $-5546028.00 | $-3557646.00 | $922390.00 | $-834044.00 | $-31458.00 | $-87.27 |
| EPS (Diluted) | $-45538416.00 | $-17584638.00 | $-19578811.00 | $-125727793.00 | $-5546028.00 | $-3557646.00 | $921915.00 | $-834044.00 | $-31458.00 | $-87.27 |
| Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | $6 | $8 | $9 | $21 | $767 | $3155 |
Price
| Price | $1.72 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABP · BCDA · CERO · EPIX · ERNA · HCWB · INAB
Explore sector: Healthcare · Biotechnology
More sections of APVO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks